Literature DB >> 20142632

ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement.

D Miljic1, M Joksimovic, M Doknic, M Ivovic, M Djurovic, S Pekic, M Tancic, I Soldatovic, M Stojanovic, Dj Nale, Dj Macut, S Damjanovic, V Popovic.   

Abstract

BACKGROUND: Overexpression of ghrelin and vasopressin (V3) receptors demonstrated on corticotrophe adenomas accounts for exaggerated ACTH and cortisol responses to ghrelin and desmopressin (DDAVP) in patients with Cushing's disease (CD). AIM: In this study we have compared ACTH and cortisol responsiveness to DDAVP and ghrelin in CD patients with and without adrenal enlargement. SUBJECTS AND METHODS: Ghrelin and DDAVP tests were performed in 15 patients with CD (7 with and 8 without signs of adrenal enlargement) with CRH test in 8 patients. In 7 age and sex-matched healthy subjects, ghrelin test was performed. Plasma ACTH and serum cortisol concentrations were measured after ghrelin, DDAVP and CRH. Growth hormone was measured after stimulation with ghrelin.
RESULTS: Significantly higher baseline and peak ACTH and cortisol concentrations after ghrelin were observed in all patients with CD compared to healthy control subjects. Patients with CD and adrenal enlargement had significantly lower baseline and peak ACTH concentrations after stimulation with ghrelin compared to CD patients without adrenal enlargement, while cortisol levels at baseline and after ghrelin administration were similar. Three out of seven patients with CD and adrenal enlargement did not respond to DDAVP while they responded well to CRH and ghrelin.
CONCLUSION: Patients with CD and adrenal enlargement pose special diagnostic problems. They may have lower baseline ACTH levels and may not respond to DDAVP while they respond to ghrelin and CRH. Despite increased endogenous cortisol levels in CD, cortisol responses to ghrelin and CRH are preserved in patients with CD and adrenal enlargement.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20142632     DOI: 10.1007/bf03346641

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  The response of corticotropin and adrenal steroids to desmopressin stimulation in patients with various forms of hypercortisolism.

Authors:  Eugenia I Marova; Nikolay P Goncharov; Galina S Kolesnikova; Svetlana D Arapova; Anastasiya M Lapshina
Journal:  Hormones (Athens)       Date:  2008 Jul-Sep       Impact factor: 2.885

3.  The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors.

Authors:  M Korbonits; S A Bustin; M Kojima; S Jordan; E F Adams; D G Lowe; K Kangawa; A B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 4.  Mechanisms of disease: the adrenocorticotropin receptor and disease.

Authors:  Adrian J L Clark; Louise A Metherell
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-05

5.  Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Authors:  Silvia Regina Correa-Silva; Sérgio Oliva Nascif; Ana-Maria Judith Lengyel
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity.

Authors:  S Tsagarakis; V Vasiliou; P Kokkoris; G Stavropoulos; N Thalassinos
Journal:  Clin Endocrinol (Oxf)       Date:  1999-10       Impact factor: 3.478

7.  The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

Authors:  M Korbonits; G Kaltsas; L A Perry; P Putignano; A B Grossman; G M Besser; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  1999-07       Impact factor: 5.958

8.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

9.  The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion.

Authors:  S Tsagarakis; C Tsigos; V Vasiliou; P Tsiotra; J Kaskarelis; C Sotiropoulou; S A Raptis; N Thalassinos
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

10.  Molecular pharmacology of human vasopressin receptors.

Authors:  M Thibonnier; D M Conarty; J A Preston; P L Wilkins; L N Berti-Mattera; R Mattera
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

View more
  1 in total

Review 1.  Clinical review: The human experience with ghrelin administration.

Authors:  Margaret C Garin; Carrie M Burns; Shailja Kaul; Anne R Cappola
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.